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Abstract Neuroendocrine tumors (NETs) arise from dissem-
inated neuroendocrine cells and express general and specific
neuroendocrine markers. Neuropeptide S receptor 1 (NPSR1)
is expressed in neuroendocrine cells and its ligand neuropep-
tide S (NPS) affects cell proliferation. Our aim was to study
whether NPS/NPSR1 could be used as a biomarker for neu-
roendocrine neoplasms and to identify the gene pathways
affected by NPS/NPSR1. We collected a cohort of NETs
comprised of 91 samples from endocrine glands, digestive
tract, skin, and lung. Tumor type was validated by immuno-
staining of chromogranin-A and synaptophysin expression
and tumor grade was analyzed by Ki-67 proliferation index.
NPS and NPSR1 expression was quantified by immunohisto-
chemistry using polyclonal antibodies against NPS and
monoclonal antibodies against the amino-terminus and
carboxy-terminus of NPSR1 isoform A (NPSR1-A). The
effects of NPS on downstream signaling were studied in
a human SH-SY5Y neuroblastoma cell line which
overexpresses NPSR1-A and is of neuroendocrine ori-
gin. NPSR1 and NPS were expressed in most NET
tissues, with the exception of adrenal pheochromocyto-
mas in which NPS/NPSR1 immunoreactivity was very
low. Transcriptome analysis of NPSR1-A overexpressing
cells revealed that mitogen-activated protein kinase
(MAPK) pathways, circadian activity, focal adhesion,
transforming growth factor beta, and cytokine–cytokine
interactions were the most altered gene pathways after
NPS stimulation. Our results show that NETs are a
source of NPS and NPSR1, and that NPS affects cancer-
related pathways.
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Introduction
Neuropeptide S receptor 1 (NPSR1 previously known as
GPRA and GPR154) is a G protein-coupled receptor that
induces intracellular signaling upon stimulation by neuropep-
tide S (NPS) via mobilization of calcium, increased cyclic
adenosine monophospate (cAMP) levels, and activation of the
mitogen-activated protein kinase (MAPK) pathway [1, 2].
NPSR1 encodes several splice variants in humans, but only
two full-length variants with unique intracellular carboxy-
termini, NPSR1-A and NPSR1-B, are expressed on the cell
surface [2]. NPSR1 is mostly expressed in the central nervous
system [3], but also in specific peripheral cell types, such as
monocytes/macrophages [4–6] and neuroendocrine cells of
the gut [7, 8]. The NPSR1 locus has shown genetic associa-
tions with inflammatory diseases, such as asthma [9–16],
inflammatory bowel disease [17], and rheumatoid arthritis
[18, 19], as well as with anxiety [20] and various stress-
related phenotypes [21–24]. NPS controls multiple neuroen-
docrine and behavioral responses, such as stress reactions in
rodents [25–28]. In addition, NPS modulates cell growth of
human Colo205 colon cancer cells [1] and porcine splenic
lymphocytes [5]. In an NPSR1-A overexpressing human em-
bryonic kidney epithelial cell line, NPS stimulation increased
expression of genes that encode peptide hormones and neu-
ropeptides secreted by enteroendocrine cells [7]. Tran-
scriptome analyses revealed that NPSR1-A and NPSR1-B
regulate essentially identical sets of genes, but the signaling
effects were stronger with NPSR1-A [29, 30].
Neuroendocrine cells are distributed widely throughout the
body as disseminated cells or glands. Tumors originating from
neuroendocrine cells are rare [31]. They share uniform histo-
logical hallmarks, but in addition to morphology diagnosis of
neuroendocrine tumors (NETs) is based on cell-specific
markers that can be detected by immunohistochemistry (i.e.,
chromogranin-A and synaptophysin). In addition, the prolif-
eration marker Ki-67 is essential for determining tumor grade
and predicting prognosis for gastroenteropancreatic (GEP)
NETs. New tumor specific and prognostic markers for the
diagnosis of NETs are still needed.
Stress responses activate the neuroendocrine and sympa-
thetic nervous system, and can impact on cancer development
by immune dysregulation. Because the NPS/NPSR1 system
acts on the hypothalamic–pituitary–adrenal (HPA) axis to
affect stress response and has direct and indirect effects on
immunity, we hypothesized that NPSR1 may have important
effects on neuroendocrine neoplasms. To evaluate whether
NPS/NPSR1 might be used as markers for certain NETs, we
studied the expression of NPS and NPSR1 in neuroendocrine
tumors from different organs. NET diagnosis was confirmed
through chromogranin-A and synaptophysin immunostaining
and NET grade was analyzed by Ki-67 proliferation
index (PI). To characterize signaling pathways affected
by NPS/NPSR1, we analyzed the effects of NPS on the global
gene expression pattern of a human SH-SY5Y neuroblastoma
cell line which overexpresses NPSR1-A and is of neuroendo-
crine origin. Our results show that NPS and NPSR1 are
expressed in NETs, and NPS activates pathways important
in cancer development.
Materials and methods
Tumor material
We collected 91 paraffin-embedded tissue samples of NET
from rectum, ileum, skin, lung, thymus, appendix, parathy-
roid, thyroid, stomach, pancreas, liver metastasis, adrenal
medulla, and extra adrenal ganglions (Table 1). Paraffin-
embedded tissue samples from patients who underwent sur-
gery for histologically confirmed colorectal cancer [32] were
used to assess expression of NPSR1 in adenocarcinomas. The
samples were collected at the Department of Pathology of
HUSLAB and Haartman Institute, University of Helsinki.
The study protocol has been approved by the Ethics Committee
of Helsinki University Central Hospital (3990/04/046/07).
Antibodies
For immunohistochemistry, mouse monoclonal antibodies
against the synthetic peptide CREQRSQDSRMTFRERTER
of the C-terminus of isoform A (NPSR1-A, amino acids 336–
354) and against the synthetic peptide TEGSFDSSGT
GQTLDSSPVA (NPSR1-N, amino acids 6–20) correspond-
ing to the extracellular N-terminus of NPSR1 were used [7,
30]. Anti-mouse IgG antibodies (1:4,000,000, R0614, Vector)
were used as an isotype control. Rabbit polyclonal anti-NPS
antibodies (0.6 μg ml−1) were purchased from Abcam
(Cambridge, UK). Rabbit IgG (1:500,000, R923, Vector)
was used as a negative control. Antibodies against
chromogranin-A (1:800) were purchased from Dako
(Glostrup, Denmark) and Novocastra antibodies against
synaptophysin (1:50) from Leica Biosystems. Chromogranin-
A and synaptophysin expression were used to confirm the
diagnosis.
Tissue microarray construction and immunohistochemical
techniques
Histopathological diagnosis was re-evaluated on hematoxy-
lin–eosin (HE) sections by an endocrine pathologist (JA), who
also selected representative areas of each tumor for construc-
tion of tissue microarray (TMA) blocks. One-millimeter-
diameter punctures were taken from the borders and central
area of each tumor with a semiautomatic tissue microarray
instrument (Beecher Instruments, Silver Spring, MD, USA).
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Three parallel serial blocks were constructed, all including
duplicate samples from each tumor.
For immunohistochemical analysis, 4 μm sections were cut
from TMA blocks and placed on charged SuperFrost Plus
slides (Thermo Scientific, Fremont CA, USA). After
deparaffinization, tissue sections were pretreated in a pretreat-
ment module (LabVision UK Ltd, UK) with Tris–HCl buffer
pH 8.5 (NPSR1-A, NPSR1-N, chromogranin-A,
synaptophysin) or Target retrieval solution (Dako) (NPS).
Microwave antigen retrieval in Tris–EDTA pH 9.0 was used
for Ki-67 antigen. After heat-mediated antigen retrieval, slides
were cooled down to room temperature and treated with
Peroxidase-Blocking Solution, Dako REAL (Dako). Immu-
nohistochemical staining was performed with polymer detec-
tion kit EnVisionTM (Dako) in a LabVision Autostainer 480
(Thermo Scientific, Fremont CA, USA). The anti-NPSR1-A
(1:3,000), NPSR1-N (1:400), and NPS (1:500) (Abcam,
Cambridge, UK) antibodies were incubated for 1 h, and
the Ki-67 antibody (1:200) (cloneMIB-1, Dako) for 30 min at
room temperature. The slides were counterstained with
Mayer’s Hematoxylin (Dako) and mounted in aqueous
mounting medium (Aquamount, BDH, Poole, UK).
The immunoreactivity of NPS as well as the staining for
both N-terminus and C-terminus of NPSR1 was independent-
ly analyzed by two inspectors (LS, JH) using a scale of 0–3,
and the consensus value representing the highest value of
immunoreactivity in the six parallel spots was used for final
analysis.
Assessment of PI
PI was assessed by by image analysis software, ImmunoRatio
[33, 34]. Image capture was performed by Nikon Eclipse 80i
light microscope (×40 objective) connected to the Digital
Sight DS-5 M (Nikon) digital camera and NIS-Elements F
3.0 image capture software. From every core biopsy, one
digital image (JPEG format, Resolution 1,280×960) was cap-
tured from the most proliferative area of the tumor covering
50 % of the core biopsy. Using the ImmunoRatio’s Advanced
Mode setting, threshold values for hematoxylin (−10) and
DAB [10] were adjusted without correction equation. A blank
field image was taken to balance uneven illuminations in the
final digital images. Image analysis settings were kept the
same after the light exposure (Manual exposure, 10 ms, Gain
1×) and thresholds were considered good. Of all the images
available from each tumor, the highest PI was recorded.
Cell culture
African green monkey kidney fibroblast cell line COS-7 was
grown in Dulbecco’s modified Eagle’s medium (DMEM)
containing GlutaMAX-I and 1 mM sodium pyruvate supple-
mented with 10 % fetal bovine serum (FBS), 100 U/ml
penicillin, and 100 mg/ml streptomycin at 37 °C in a CO2
conditioned, humidified incubator. For the experiments, 4–5×
104 cells were seeded on glass coverslips on 24-well plates
and cultured in DMEM (Gibco, High glucose) with 10% fetal
bovine serum. After 24 h, the cells were transfected with
recombinant full-length NPSR1 constructs fused with either
red fluorescence protein (NPSR1-A-pDsRed) or green fluo-
rescent protein (NPSR1-B-GFP) using 1.3 μl Fugene HD and
0.5 μg of DNA per well. Construction of the expression
vectors has been described earlier [35]. After 24 h, the cells
were fixed with 4 % paraformaldehyde in phosphate-buffered
saline (PBS) for 5 min. After fixation, the cells were perme-
abilized with 0.1 % Triton X-100 in PBS for staining with
Table 1 Study material
Tissue Histological diagnosis Number Male Female Age PI ≤2 % PI 3–20 % PI >20 %
Stomach Neuroendocrine neoplasma 6 4 2 65 – 3 3
Ileum Neuroendocrine neoplasma 5 3 2 64 3 2 –
Appendix Neuroendocrine neoplasma 7 3 4 51 4 3 –
Rectum Neuroendocrine neoplasma 6 1 4 58 2 3 1
Pancreas Neuroendocrine neoplasma 13 4 9 50 4 8 1
Lung Carcinoids, small cell carcinoma 14 4 10 59 4 3 7
Thymus Neuroendocrine carcinoma 1 – 1 43 – 1 –
Thyroid Carcinoma medullare 5 2 3 46 3 2 –
Parathyroid Adenoma 5 1 4 58 4 1 –
Adrenal gland Pheochromocytoma 5 3 2 56 2 3 –
Extra adrenal Paraganglioma 5 2 3 69 3 2 –
Skin Merkel cell carcinoma 4 3 1 77 – – 4
aDistribution of proliferation index (PI) values proposed by WHO 2010 was used for grading of gastroenteropancreatic neuroendocrine tumors (GEP-
NETs) to simplify the presentation of PI values. GEP-NETs were categorized into NET G1 tumors (PI ≤2 %), NET G2 tumors (PI=3–20 %), and NEC
G3 carcinomas (PI >20 %)
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anti-NPSR1-A antibodies, whereas the cells for anti-NPSR1-
N staining were left untreated. The cells were incubated in 3%
bovine serum albumin (BSA) in PBS for 30 min to block
nonspecific binding of the antibodies. Subsequently, the cells
were incubated with primary antibodies for 1 h followed by
three washing steps with PBS and staining with secondary
anti-mouse antibodies labeled with either green (FITC) or red
(TRITC) fluorescent tags for 30 min.
Finally, the nuclei were stained with 40,6-diamino-2-
phenylindole (DAPI, Sigma-Aldrich), and the cells were
mounted on glass slides with ProLong Gold antifade reagent
(Invitrogen).
SH-SY5Y human neuroblastoma cells (ATCC, CRL-
2266™) were grown in DMEM-GlutaMAX™-I medium
(Invitrogen) supplemented with 10 % fetal calf serum,
100 U/ml penicillin, and 100 U/ml streptomycin at 37 °C in
a 5 % CO2 humidified incubator. Transfections were done
with FuGENE reagent (Roche) according to manufacturer’s
protocols. In order to obtain stable clones, SH-SY5Y cells
were transfected with NPSR1-A-GFP plasmid and selected
with 500 μg/ml G418 for 3 weeks.
Bacterial lysates
The monoclonal antibodies were analyzed by immunoblotting
of recombinant NPSR1 fragments expressed with the
pGEX 4 T-3 glutathione-S-transferase (GST) fusion ex-
pression vector (Amersham Biosciences, Buckinhamshire,
UK) as GST fusion protein in Escherichia coli and as a
dihydrofolate reductase (DHFR) fusion protein (Qiagen)
as described earlier [4]. The constructs for immunoblotting
experiments were designed to express the following se-
quences: CREQRSQDSRMTFRERTER (NPSR1-A) and
TEGSFDSSGTGQTLDSSPVA (amino terminus of NPSR1,
NPSR1-N).
Microarray sample preparation and analysis
Cells (2×106) were plated, grown O/N, and treated with
100 nM NPS (New England Peptide LLC) for 3 h.
Kit (Qiagen). cDNA was synthesized with TaqMan Re-
verse Transcription Reagents (Applied Biosystems). A
total of 12 hybridizations (technical triplicates) and
scannings (Affymetrix GeneChip Scanner 3000) were
carried out using standard Affymetrix protocols for gene
expression (www.affymetrix.com) with the HGU133plus2
array. Triplicates were analyzed for each of the four
samples: untreated parental SHSY5Y and NPSR1-A-
GFP1 cells and NPS treated parental and NPSR1-A-
GFP1 cells.
Data analysis for microarrays
Microarray raw data files (.CEL files) were imported into R v.
2.15 (http://cran.r-project.org) and analyzed with the
Bioconductor suite v. 2.12 [36]. After quality check operated
by affyPLM package [37], the probes were re-annotated and
re-assigned to newly-defined probe sets according to the
Entrez gene IDs (http://brainarray.mbni.med.umich.edu/
Brainarray/Database/CustomCDF/16.0.0/entrezg.asp) and
the data were preprocessed with the RMA algorithm [38], as
implemented in the Affy package [39]. Subsequently,
differential expression was evaluated by fitting a linear
model followed by empirical Bayes pairwise comparisons as
implemented into the package limma [40]. Genes with p<0.01
after Benjamini and Hochberg post hoc correction [41] were
considered to be differentially expressed.
Quantitative RT-PCR
Statistical analysis
The correlations between marker expression levels and Ki67
PI were analyzed using two-tailed tests and Pearson
correlation, r. Results are expressed as mean ± SEM
and p values of <0.05 were considered statistically
significant. Statistical analyses were performed using
SPSS 17.0 software program (SPSS Inc., Chicago, IL,
USA).
Results
Specificity of the monoclonal anti-NPSR1 antibodies
Monoclonal antibodies against the N-terminus (anti-NPSR1-
N) and C-terminus of NPSR1-A (anti-NPSR1-A) were used to
study the expression of NPSR1 in NETs. The specificity of
these antibodies has been previously characterized using flow
cytometry, immunoblotting experiments, and immunostaining
of skin and small intestine sections [7, 30]. In the current
study, epitope specificity of the monoclonal anti-NPSR1 an-
tibodies was further studied in immunoblotting experiments of
recombinant NPSR1 constructs expressing the corresponding
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RNAwas extracted from cell lysates using RNeasy®PlusMini
Kit (Qiagen). cDNA was synthesized with TaqMan Reverse
Transcription Reagents (Applied Biosystems). Quantitative
real-time PCR was done using SYBR Green method with
primers as listed in Supplementary Table 1. Quantifications
were done using relative standard curve method and the
results were normalized with the expression levels of
GAPDH. Fold changes were calculated by comparing to the
expression level in non-treated cells.
Total RNA was extracted using RNeasy® Plus Mini
peptide sequences produced in E. coli and by immunocyto-
chemistry of the COS-7 cell line transfected with recombinant
full-length NPSR1 constructs. Immunoblotting analyses of
the bacterial lysates indicate that the monoclonal antibodies
against NPSR1-A and NPSR1-N are epitope specific
(Supplementary Fig. 1). The correct expression of the
recombinant proteins was confirmed through Coomassie
Blue staining.
Specificity of the monoclonal NPSR1 antibodies in immu-
nocytochemistry was tested on COS-7 cells, transfected with
recombinant full-length NPSR1 constructs fused with either
red fluorescence protein (NPSR1-A-pDsRed) or green fluo-
rescent protein (NPSR1-B-GFP). Binding of the primary an-
tibodies was visualized using secondary anti-mouse antibod-
ies labeled with either green (FITC) fluorescent tags for
NPSR1-A-pDsRed constructs or red (TRITC) fluorescent tags
for NPSR1-B-GFP construct. Overlay of the two images
(FITC/TRITC) resulted in similar patterns indicating that the
antibodies were epitope specific also for the full-length
NPSR1 isoforms (Fig. 1).
NPSR1 is widely expressed in NETs
We have previously shown that NPSR1 is expressed in
enteroendocrine cells of the gut [7]. To analyze whether
NPS/NPSR1 is a biomarker for NET, NPS and NPSR1
immunoreactivity was assessed on the NET TMA
(Table 1). For six samples, no results were obtained
either because of missing tumor tissue cores on the
TMA or unrepresentative tissue material. NPSR1 and
NPS were widely expressed in NETs (Fig. 2). Pheochro-
mocytomas of the adrenal medulla showed no or only
very low immunoreactivity for NPSR1 and NPS where-
as extra-adrenal sympathetic paragangliomas showed
stronger reactivity for the antigens (Fig. 3). Staining
with the anti-NPSR1-N antibodies which detect extracel-
lular epitopes of both NPSR1-A and NPSR1-B isoforms
resulted in clear staining of the cellular membranes (Fig, 3a)
whereas staining with the anti-NPSR1-A antibodies which
detect intracellular epitopes of NPSR1-A resulted mostly in
cytoplasmic staining. Expression of NPS was mostly
DAPI
DAPI
DAPI
NPSR1-A-pDsRed MergedAnti-NPSR1-A
Anti-NPSR1-N Merged
Merged
NPSR1-A-pDsRed
NPSR1-B-GFP Anti-NPSR1-N
Fig. 1 Epitope specificities of the monoclonal anti-NPSR1-A and anti-
NPSR1-N (detecting both NPSR1-A and NPSR1-B isoforms) antibodies
against recombinant NPSR1 proteins overexpressed in COS-7 cells. The
cell nuclei were stained with 40,6-diamino-2-phenylindole (DAPI) (left
panel). Cells were transfected with the full-length variant for NPSR1-A
fused with red fluorescence protein (NPSR1-A-pDsRed) or with the full-
length variant for NPSR1-B green fluorescent protein (NPSR1-B-GFP)
for 24 h and visualized under conventional fluorescence microscope (left
middle). Cells transfected with NPSR1-A-pDsRed were stained either
with the monoclonal anti-NPSR1-A or anti-NPSR1-N antibodies follow-
ed with secondary anti-mouse antibodies labeled with green (FITC)
fluorescent tags, and cells transfected with NPSR1-B-GFP were stained
with the monoclonal anti-NPSR1-N followed with secondary anti-mouse
antibodies labeled with red fluorescent tags (TRITC) (right middle). The
cells were permeabilized for staining with the anti-NPSR1-A antibodies,
whereas the cells for anti-NPSR1-N stainings were left untreated. Overlay
of the two images (right panel)
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cytoplasmic, and some nuclear/perinuclear expression was
also observed. Chromogranin-A expression and the Ki-67
proliferation index were inversely correlated (r=−0.551,
p<0.001).
Expression of NPSR1 is specific for NETs
To study whether expression of NPSR1 is specific for NETs or
a general marker of abnormal growth, we compared the
NPSR1-N
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Fig. 2 Expression of NPSR1-N, NPSR1-A, and NPS in NETs and colon adenocarcinomas (mean ± SEM)
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Fig. 3 Representative photomicrographs of NPSR1-N (a–c), NPSR1-A (d–f), and NPS (g–i) in NETs from pancreas (a, d, g), pheochromocytoma (b, e,
h), and paraganglioma (c, f, i). Original magnification×600
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expression of NPSR1 in colorectal adenocarcinomas (n=25)
and NETs. As shown in Fig. 2, NPSR1 was not expressed in
the adenocarcinoma samples, but was expressed in the NETs
of the GI tract (rectum, ileum), suggesting that expression of
NPSR1 might be specific for NETs. The colorectal adenocar-
cinomas did not express the neuroendocrine cell marker
chromogranin-A (data not shown).
NPSR1 expression in metastases
To further assess the impact of NPSR1 expression on meta-
static potential, NPSR1 immunoreactivity was analyzed in
primary NETs originating from the pancreas and ileum and
in tumor metastasis samples from the same tumors (Table 2).
We found no difference in expression of NPSR1 between
primary NETs and their metastases.
NPS induces cancer-related pathways in SH-SY5Y cells
over-expressing NPSR1
Endogenous expression of NPSR1 in cultured cells is low
with the exception of human Colo205 colon cancer cells [1].
We used human SH-SY5Y neuroblastoma cells, which over-
express NPSR1-A, to study downstream targets of the NPS-
NPSR1 signaling pathway by HGU133plus2 array
(Affymetrix), which contains over 47,000 probe sets. Cells
treated with 100 nM NPS for 3 h were compared with non-
treated cells. Additional comparisons were done to parental
SH-SY5Y cells with and without NPS treatment. Using cutoff
of 1.25- and 0.75-fold changes, 552 and 184 probe sets were
found to be up- or down-regulated, respectively, in NPS
treated vs. untreated NPSR1-A-GFP overexpressing cells.
The genes are listed in Supplementary Material, Supplemen-
tary Table 2. NPS treatment induced small changes also in
parental SH-SY5Y cells (listed in Supplementary Material,
Supplementary Table 3) possibly due to low endogenous
expression of NPSR1.
KEGG pathway mapping of the 552 upregulated tran-
scripts found in the comparison of NPS treated vs. non-
treated cells showed enrichment of expression of genes of
pathways related to the MAPK pathways (with p value of
2.3×10−9), “circadian activity” (p=5.6×10−9), focal adhesion,
transforming growth factor beta (TGFB), and cytokine–cyto-
kine interactions (Supplementary Table 4).
To further validate the results, genes that belong to the
MAPK pathway were selected from the list and expression
was studied by quantitative real-time PCR (qRT-PCR) for the
time course and dose responsiveness of the induction. The
genes were growth arrest and DNA-damage-inducible, alpha
(GADD45A), nuclear receptor subfamily 4, group A, member
1 (NR4A1), nuclear factor of kappa light polypeptide gene
enhancer in B-cells 1 (NFKB1), and v-myc avian
myelocytomatosis viral oncogene homolog (MYC). As shown
in Fig. 4, expression of MYC and GADD45A peaked at 3 h,
and for NR4A1 and NFKB1, the highest levels were seen at
6 h. Parental SH-SY5Y cell line was used as a control for the
experiments.
Discussion
In this study, we investigated whether NPS or NPSR1 might
be used as biomarker for NET in a wide panel of neuroendo-
crine tumors, characterized by assessing the Ki-67 prolifera-
tion index and chromogranin-A and synaptophysin expres-
sion. Our results show that NPS and NPSR1 are expressed in
NETs. The results from the cell line experiments indicate that
stimulation of NPSR1 with NPS results in activation of path-
ways that are relevant for cancer development.
We usedmonoclonal antibodies against the N-terminus and
C-terminus of NPSR1 to characterize its expression in NETs.
In previous studies, we found anti-NPSR1-N antibodies to be
specific for HEK-293 cells transiently overexpressing
NPSR1-A and NPSR1-B in flow cytometry experiments
[30], and anti-NPSR1-A antibodies specific for HEK-293
cells stably overexpressing NPSR1-A in immunoblotting
experiments [7]. Furthermore, staining of small intestinal
mucosa with monoclonal anti-NPSR1-A antibodies and
carefully characterized polyclonal antibodies against
NPSR1-A [2, 4, 9] confirmed that NPSR1-A is
expressed in the enteroendocrine cells of the gut [7].
Another study confirmed that staining of ileum, duode-
num, colon, and rectum samples with publicly available
(www.proteinatlas.org) affinity-purified (monospecific)
NPSR1-antibodies resulted in strong and specific stain-
ing of enteroendocrine cells [8]. The results from the
current study confirm the epitope specificity of monoclonal
NPSR1 antibodies and the cell surface expression of NPSR1
in NETs.
Table 2 Metastases
Case Tissue PI % NPSR1-N NPSR1-A
1 Primary Pancreas 5 1 1
Metastase Liver 4 1 1
2 Primary Pancreas 1 2 2
Metastase Liver 2 2 2
3 Primary Pancreas 70 3 1
Metastase Lymph node 80 2 1
4 Primary Pancreas 7 2 2
Metastase Liver 28 2 2
5 Primary Ileum 1 2 2
Metastase Liver – 3 2
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The WHO classification of GEP-NETs is based on the
proliferation rate, and the tumors are categorized into different
grades depending on proliferation activity: NET G1 tumors
PI=0–2 % and NET G2 tumors PI=3–20 %. Neuroendocrine
carcinomas (NEC) have a PI over 20 %. Our results show that
the expression of NPS/NPSR1 is specific for NETs as NPSR1
was expressed in the NETs of the GI tract but not in colorectal
adenocarcinoma samples from the same primary site.
One of our most interesting findings was that NPSR1 is
expressed in sympathetic extra adrenal paragangliomas but not
in pheochromocytomas arising from the adrenal medulla.
Paragangliomas are classified either as parasympathetic or
sympathetic paraganglioma depending on their origin. Unlike
parasympathetic paragangliomas, pheochromocytomas and
sympathetic paragangliomas usually produce catecholamines
and are more frequently malignant. Sympathetic
paragangliomasmetastasizemore frequently than pheochromo-
cytomas [42, 43]. Currently, only three predictors of metastatic
potential in patients with pheochromocytomas and sympathet-
ic paragangliomas are well recognized: primary tumor loca-
tion (adrenal pheochromocytomas vs. extra-adrenal sympa-
thetic paragangliomas), primary tumor size, and germline
mutations of the SDHB (succinate dehydrogenase complex,
subunit B, iron sulfur) gene. More than half of the patients
with metastatic sympathetic paraganglioma have an underly-
ing SDHB mutation. These mutations are also found in 5–
10 % of patients with metastatic pheochromocytomas. As the
role of NPS in these tumors appears to be associated with
malignant outcome, lack of expression in pheochromocyto-
mas may be related to benign tumor behavior.
In previous studies, NPS stimulation was found to stimu-
late growth of Colo205 human colon cancer cells, possibly via
enhanced phosphorylation of MAPK [1], and provoked pro-
liferation of pig splenic lymphocytes [5]. In an NPSR1 over-
expressing human embryonic kidney epithelial cell line, NPS
stimulation resulted in decreased cell proliferation [2]. The
current grading system for NETs is based on mitotic rate and
proliferation index. Ki-67 is an established marker of cell
proliferation that is expressed in all stages of the cell cycle
except for the resting phase. PI is generally considered to be
applicable for low-grade tumors, such as tumors of the GI
tract. Although proliferation is an essential marker and deter-
mines the prognosis and guides treatment of NETs, it does not
necessarily reflect metastatic potential. For example, small
bowel NETs may have a very low proliferation and yet be
widely metastasized. In our material, we did not find any
difference in NPSR1 expression in primary vs. metastatic
tumors. NPS might not take part in the processes involved in
NET metastasis (vascular invasion, homing and tumor neo-
vascularization) [44].
Signaling pathways downstream of NPSR1 have been
extensively investigated using HEK293 cells overexpressing
NPSR1 stimulated with 1–2 μMNPS for 6 h [29, 30, 45]. We
used SH-SY5Y neuroblastoma cells with the same arrays
(HGU133plus2) and the same cutoff (B value >7). However,
we used 100 nM NPS and 3 h exposure, which allowed
us to asses early induced genes. Pathway analysis revealed
that MAPK is the most significantly induced signaling path-
way that was previously linked with NPSR1. We selected
genes that belong to the MAPK pathway and showed that
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Fig. 4 Time and dose course of the gene induction upon NPS treatment.
Parental SH-SY5Y cells and cells stably transfected with the NPSR1-A-
GFP construct were stimulated a with NPS 100 nM for 3–24 h or b with
0.001–1 μM NPS for 3 h. mRNA levels of growth arrest and DNA-
damage-inducible, alpha (GADD45A), nuclear receptor subfamily 4,
group A, member 1 (NR4A1), nuclear factor of kappa light polypeptide
gene enhancer in B-cells 1 (NFKB1), and v-myc avian myelocytomatosis
viral oncogene homolog (MYC) were measured by quantitative RT-PCR.
The results are shown as average of three biological replicates (time) or
three technical replicates (dose) (mean ± SD). The relative change in
expression was calculated by comparing to the expression levels in
unstimulated cells
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their regulation is dependent on NPS stimulation. The other
highly significant gene ontology group induced by NPS was
the circadian clock gene pathway. Interestingly, phenotypical
analysis of Npsr1 knockout mice has revealed deficits in
circadian activity [46, 47], and central administration of NPS
induces wakefulness in various rodent models [3]. Further-
more, polymorphism in NPSR1 was associated with bedtime
and sleepiness in a genome-wide association study [48]. Mo-
tivated by these findings, we previously showed that NPS
affects circadian clock gene expression in the same SH-
SY5Y cell line with NPSR1 overexpression [35]. Of these
genes that regulate circadian molecular clock machinery,
NPAS2, PER1, CRY1, and RORAwere among the most affect-
ed genes in the current microarray experiment. Epidemiolog-
ical studies have shown that disruption of sleep/circadian
control due to jet lag, shift work, or increased exposures to
light at night has widespread effects on all aspects of neuro-
endocrine function including elevated risk for cancer. Further-
more, circadian clock regulates the cell cycle, DNA damage
responses, ageing, and metabolism [49]. Aberrant circadian
rhythms could lead to defects in the regulation of these pro-
cesses, which might result in tumorigenesis and tumor pro-
gression. In addition, the other pathways affected by NPS
stimulation, namely focal adhesion, TGFB, and cytokine–
cytokine interactions are highly relevant for tumor progression
and metastasis. Assembly of focal adhesion is crucial in cell
migration, and previous studies have shown that NPS stimu-
lates human monocyte chemotaxis [6] and eosinophil migra-
tion and adhesion [50]. Taken together, transcriptome analysis
of NPS/NPSR1 ligand/receptor activation is a powerful tool
that revealed novel cancer-related gene pathways many of
which have already shown to be relevant for NPS/NPSR1
function in experimental settings.
In conclusion, NPSR1 is a marker widely expressed in
NET with the exception of adrenal pheochromocytomas.
NPSR1 stimulation activates intracellular pathways relevant
for cell growth. No differences were detected between the
expression levels in primary tumor tissue and metastases.
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